Abstract:Valproate is the most effective treatment for idiopathic generalised epilepsy. Current guidance precludes its use in women of childbearing potential, unless other treatments are ineffective or not tolerated, because of high teratogenicity. This risk was recently extended to men. New guidance will limit use both in men and women aged <55 years, resulting in withdrawal of valproate from men already taking it, as occurs for women. Whether there are risks of personal harm (including injury or death) associated with valproate withdrawal has not yet been quantified for men or women on valproate, meaning clinicians cannot reliably counsel either sex when discussing valproate withdrawal with them, despite that this concern may be at the forefront of patients' and clinicians' minds. We assessed whether there are any morbidity or mortality risks associated with valproate withdrawal in young men and women. We performed a retrospective cohort study of internationally derived electronic health data within the TriNetX Global Collaborative Network. Included were men and women aged 16–54 years with ≥1 epilepsy disease or symptom code between 01/12/2017–01/12/2018 and ≥2 valproate prescriptions over the preceding two years (01/01/2015–30/11/2017). 5-year propensity-matched risks of mortality and a range of morbidity outcomes were compared between those remaining on vs. withdrawn from valproate during the 01/12/2017–01/12/2018 recruitment period, regardless of whether switched to another antiseizure medication. Survival analysis was undertaken using Cox-proportional hazard models, generating hazard ratios (HRs) with 95% confidence intervals (CIs). 8,991 men and 5,243 women taking valproate were recruited. 28% of men and 36% of women were subsequently withdrawn from valproate. Valproate withdrawal was associated with significantly increased risks of emergency department attendance (HRs overall: 1.236 (CI 1.159–1.319), men: 1.181 (CI 1.083–1.288), women: 1.242 (CI 1.125–1.371)), hospital admission (HRs overall: 1.160 (CI 1.081–1.246), men: 1.132 (CI 1.027–1.249), women: 1.147 (CI 1.033–1.274)), falls (HRs overall: 1.179 (CI 1.041–1.336), men: 1.298 (CI 1.090–1.546)), injuries (HRs overall: 1.095 (CI 1.021–1.174), men: 1.129 (CI 1.029–1.239)), burns (HRs overall: 1.592 (CI 1.084–2.337)), and new-onset depression (HRs overall 1.323 (CI 1.119–1.565), women: 1.359 (CI 1.074–1.720)). The risk of these outcomes occurring was 1–7% higher in those withdrawn from valproate than in those remaining on valproate. Overall, valproate withdrawal was not associated with increased mortality. These results may help patients and clinicians have a more informed discussion about personal safety when considering valproate withdrawal.

The patient voice: valproate, topiramate and MHRA regulation

New valproate regulations, informed choice and seizure risk

Time to re-evaluate the risks and benefits of valproate and a call for action

National compliance with UK wide guidelines for usage of valproate in women of childbearing potential

The preconception care experiences of women with epilepsy on sodium valproate

An international study to investigate and optimise the safety of discontinuing valproate in young men and women with epilepsy: protocol

Outcomes Of Sustained-Release Formulation Of Valproate And Topiramate Monotherapy In Patients With Epilepsy: A Multi-Centre, Cohort Study

Impact of regulatory safety warnings and restrictions on drug treatment of epilepsy

Valproate prescription to women of childbearing age in English primary care: repeated cross-sectional analyses and retrospective cohort study

Seizure medication and planned pregnancy: balancing the risks and outcomes

Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate

Effectiveness of risk minimization measures for valproate: a drug utilization study based on implementation of a risk minimization programme in Europe, analysis of data from the UK

Paternal Valproate Treatment and Risk of Childhood Neurodevelopmental Disorders: Precautionary Regulatory Measures Are Insufficiently Substantiated

Unmet needs of people with epilepsy: A qualitative study exploring their journey from presentation to long-term management across five European countries

Morbidity and mortality risks associated with valproate withdrawal in young men and women with epilepsy

The safety of anti-epileptic drug regimens: a qualitative study of factors determining the success of counselling women before conception

The lived experience of young adults with Fetal Valproate Spectrum Disorder, and the perspective of their parents: A qualitative study

Valproate impact and sex-dependent seizure remission in patients with idiopathic generalized epilepsy

Topiramate ban in women of childbearing potential with idiopathic generalized epilepsy: Does effectiveness offset the teratogenic risks?

Caregiver Perspective of Benefits and Side Effects of Anti-Seizure Medications in CDKL5 Deficiency Disorder from an International Database

The experiences of adolescents and young adults with epilepsy: A systematic review and meta-synthesis of qualitative studies